nnc0519-0130
Obesity Disorder
Novo Nordisk A/SPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 49/ 100
- Competitive Position
- 59/ 100
Competitive context
574 Active assets in the Obesity Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
vi-0521 VIVUS LLC | Phase 4 | BBB |
Deoxycholic Acid University of California, San Diego | Phase 4 | BBB |
Efsubaglutide Alfa The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 4 | BBB |
asc30 Ascletis Pharma (China) Co., Limited | Phase 2 | BBB |
Tirzepatide Royal North Shore Hospital | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
nnc0519-0130 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →